Tuesday November 24 2009 | Biotechnology feed | All feeds
See also: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor.html for full listing. Pipeline Insight: Non-Insulin Antidiabetics - Incretin mimetics, leaders in a diverse pipeline RNA therapy: the next big thing after monoclonal antibodies? Commercial Insight: Pain Market Overview - Non-traditional analgesics and opioid reformulations to sustain sector growth M&A trends in Pharma Strategic Perspectives: Antidyslipidemics Current market is not conducive for growth Emerging Markets Series: The Pharmaceutical Market of South Korea Pipeline and Commercial Insight: Schizophrenia - Second generation depots protect market value Sales Force Effectiveness Stakeholder Insight: Osteoporosis - Generic alendronate further establishes oral bisphosphonates as gold standard Trends in Pharmaceutical Portfolio Management - Strategies to maintain profitability despite adversity Trends in Clinical Trials: Strategies to enhance clinical trial design Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types Stakeholder Opinions: Vaccine adjuvants - uncertainties rule Forecast Insight: Parkinson's Disease - Market upgrade following evidence of disease slowing with Azilect Commercial Insight: Inflammatory Bowel Disease - Convenience and compliance drive market success Forecast Insight: Dyslipidemia - Genericization and negative trial data drive market shrinking Commercial Insight: Select herpes viruses and human papilloma virus - Non-biologic interventions for oral and genital herpes, cytomegalovirus infection, herpes zoster and genital warts Forecast Insight: Antidiabetics - Switching to new molecule antidiabetics drives market growth Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape Commercial Insight: HIV - The battle for market share is getting fiercer Forecast Insight: Insomnia Orexin and serotonin receptor modulators to innovate market Commercial Insight: Antihormonal Therapy Cancer Brands - Careful lifecycle management needed to preserve brand dominance Commercial Insight: Top 20 Therapy Cancer Brands - Key brands set to consolidate advantage as competition intensifies Forecast Insight: Multiple Sclerosis - Tysabri to prevail despite safety setbacks Forecast Insight: Asthma/COPD - Little long-term future for long-acting single-agent inhalers? Biosimilars Series: Stakeholder Analysis Forecast Insight: Antihypertensives Key patent expiries prevent market growth Pipeline Insight: Cancer Overview - Lung, Brain, Head and Neck, Thyroid Commercial Insight: Targeted Therapy Cancer Brands - High growth market will see eight new blockbusters by 2017 Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming patent expiries limit market growth Generic Series: Optimizing Brand Lifecycle Management Winning Strategies to Maximize Revenue in the Face of Growing Generic Competition Pipeline Insight: Insulin antidiabetics - Return to injections alternative delivery methods fall by the wayside Stakeholder Opinions: Diagnostics in Neurology - Predictive biomarkers expand drug revenues Stakeholder Opinions: Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of market prospects for biologics expose an opportunity for cell and gene therapies Commercial and Pipeline Insight: Fibromyalgia - Approvals legitimize condition and expose underserved patient population Commercial and Pipeline Insight: Vaccines for Adults and the Elderly - New blockbuster opportunities ahead Stakeholder Insight: Asthma - Over-prescribing is common in intermittent and mild forms of asthma Monoclonal Antibodies Report: 2008 Update Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch Drug Repositioning Strategies - Serendipity by design Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses Pipeline Insight: Acute Stroke: Commercial risk offsets high unmet need Online patient recruitment and its impact on patient relationship management Pipeline Insight - Non-insulin antidiabetics Incretin mimetics leaders in a diverse pipeline Pricing and Reimbursement - Seven Major Markets Update Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard Commercial Insight: CNS Market Overview - Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors Commercial and Pipeline Insight: HRT for Menopausal Symptoms – A new class restores an old market Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine? Pipeline Insight: Non-Small Cell Lung Cancer - Pipeline set to offer only modest improvements Stakeholder Opinions: Heart Failure - When drugs do not work Pipeline Insight: Breast Cancer - Recent approvals increase pressure on pipeline candidates Commercial and Pipeline Insight: ADHD - Immature adult market continues to offer greatest commercial potential Stakeholder Opinions: Portable Inhaler Devices - Key tools to differentiate brands and survive generic pressure Stakeholder Opinions: Sepsis - The Critical Care Community Gains Critical Mass Commercial and Pipeline Insight: Opioids - Short acting and anti-abuse technologies set to fragment and grow the market Pipeline and Commercial Insight: Alzheimer's Disease - Scenario forecasts reveal vast market potential Stakeholder Opinions: Biologics in Infectious Diseases Well defined target populations are key to commercial success Pharmaceutical Supply chain strategies: Reassessing product distribution to cut costs and improve supply chain management Stakeholder Opinions: Systemic Lupus Erythematosus - Market set to enter era of biologic therapies The Pharmaceutical Industry 2008: Current and Future Trends and Strategic Issues Shaping Pharma Bone Metastases - Impending patent expiries may help make or break newer agents Emerging pharmaceutical markets Argentina and Mexico OTC Pharmaceuticals: Global Industry Guide Pharmaceuticals: Global Industry Guide 2008 Non-Hodgkin's Lymphoma - Is there room to emulate Rituxan's success? Prostate Cancer - Hormone-refractory patients still waiting for treatment breakthroughs Bausch and Lomb's Contact Lens Solution Withdrawal - ReNu MultiPlus likely to struggle in attempt to regain market share eHealthInsight Series Reaching Doctors and Patients Through New Digital Media Emerging markets series Benchmarking key countries Brazil, Russia, India, China and Turkey Commercial Insight Infectious Diseases Overview Acute Coronary Syndromes Fresh look at ACS in Europe, what is the real picture? Stakeholder Insight Diabetes Urinary Incontinence Lifecycle management strategies retain midterm market growth Commercial Insight Autoimmune Overview Market continues to prosper Generics Series Key trends and events in the 7 major markets AntiCounterfeiting Strategies Combating Fake Pharmaceuticals Stakeholder Opinions Hepatitis C Smallmolecule antivirals pave the way for triple therapy Stakeholder Opinions Myelodysplastic Syndromes First approvals spur some interest in a niche market Stakeholder Opinions NonHodgkin's Lymphoma Is there room to emulate Rituxan's success? Stakeholder Opinions Multiple Myeloma Exploring new targets for multiple drug therapy Stakeholder Opinions Endometriosis Scientific clarity will unlock market potential The Pharmaceutical Company Outlook to 2012 Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech Pipeline perspectives Peripheral artery disease Poor disease awareness hinders new agents Pipeline Insight Substance Dependence Part II Alcohol Pipeline Insight Orphan Diseases in CNS Part II Amyotrophic Lateral Sclerosis Pipeline Insight HIV Novel NNRTIs address crucial unmet need Stakeholder Insight Parkinson's Disease Evidence of neuroprotection essential to progress treatment dynamics Stakeholder Insight Inflammatory Bowel Disease Debate over early aggressive treatment continues Stakeholder Insight Prostate Cancer Hormonerefractory patients still waiting for treatment breakthroughs Stakeholder Opinions Alpha 1 Antitrypsin Deficiency Stakeholder Opinions Head and Neck Cancer Commercial and Pipeline Insight - Systemic antifungals Pipeline Insight - Orphan Diseases in CNS - Part I Huntington's Disease Licensing Strategies - Examining Today’s Pharmaceutical Licensing Trends Pipeline Insight - Substance Dependence - Part I - Nicotine Commercial and Pipeline Insight - Hepatitis B Cardiovascular market overview - Raft of patent expires threaten blockbusters Molecular Targeted Cancer Therapies Can anything else revolutionize the market Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family Acute Stroke - TPA spurs infrastructure changes for the better Renal Cancer - Targeted therapies rapidly take hold of market Antithrombotics - Market expands as disease management focuses on prevention Infertility - Optimizing a market bounded by social opinion and physician preference Commercial and Pipeline Insight Allergic Rhinitis Upper GI Disorders - Innovation needed to overcome generic threat HIV Therapy Dynamics Orthopedics: Global Industry Guide Biotechnology: Global Industry Guide Generics: Global Industry Guide Biosimilars Series Strategic issues - Potential remains uncertain Cancer Overview - Increasing diversity offers both high risk and reward Parkinson's Disease - Market to grow as first round of lifecycle management strategies succeed Pricing and Reimbursement Series NICE its impact on the UK healthcare system and beyond Neuropathic Pain - Emerging drugs fail to capitalize in lucrative market Migraine - Opportunities will exist in the wake of generic attack Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff Osteoporosis Intermittent dosing drives market growth Biosimilars Series Regulatory and development issues hurdles exist but are surmountable Hospital Antibacterials A market beyond MRSA Business Blogging for Pharma Antidiabetics Safety becomes the critical factor for success Launch Strategies Analyzing Market Trends and Regulatory Impacts Heart failure Weak pipeline dominated by new indications and add-on diuretics R&D Strategies Incremental improvements and paradigm shifts in strategy are both necessary to boost productivity Female Sexual Dysfunction Prescription Drug Pipeline Overview 2007 Pediatric and Adolescent Vaccines Patient Empowerment empowered patients can change healthcare outcomes and impact the pharmaceutical industry Antihypertensives New class opportunity offset by key patent expiries Antidyslipidemics The competitive cost-conscious antidyslipidemics market presents challenges Asthma and COPD Combination products still have blockbuster potential HIV Reshaping Treatment Paradigms Upper GI Disorders Generics will limit pipeline profit Top 20 Cancer Therapy Brands Sales of targeted therapies overtake cytotoxics in 2006 Disease Management and Drug Adherence Strategies to support patients and enhance treatment persistence Primary Brain Cancer Depression Atypical lifecycle management strategy rejuvenates depression market Insomnia Strong brand identity critical to differentiation in an increasingly crowded market Multiple Sclerosis Continued growth makes the MS market a highly attractive investment Osteoporosis Risk management and reformulation offer best defense against generic onslaught Monoclonal Antibodies Report Part I Spending on Telehealth Solutions in Europe 2007 to 2012 (Databook) Spending on Telehealth Solutions in North America through 2007 to 2012 (Databook) Irritable Bowel Syndrome Potentially profitable market is open for the taking Supportive Care in Oncology Significant growth opportunities exist in new supportive care indications Hepatocellular Carcinoma Opportune indication for novel therapies Generic Series An Introduction to the Canadian Generics Market Key trends and leading companies shaping the market Female Sexual Dysfunction Results from Datamonitor's 2005 physician survey Fibromyalgia Potentially lucrative market soon to become reality Disease Modification in Rheumatoid Arthritis Competition for the anti-TNF failure patient population increases Insomnia Targeting the sleep maintenance market Benchmarking Patent Expiries Key Factors Affecting Brand Erosion at Patent Expiry Antithrombotics Reaching the untreated prophylaxis market Dyslipidemia - Pipeline agents unlikely to rejuvenate the market Influenza Vaccines - Pandemic threat revitalizes the sector Hematological Malignancies Pursuit for the next blockbuster intensifies Multiple Sclerosis The oral revolution Pricing and Reimbursement Series Medicare Part D's progress so far Asthma Phenotypes A changing paradigm Depression Novel drugs to grow third-line market Nosocomial Infections The need for new gram-negative drugs ePrescribing Infrastructure and Impact on the Healthcare Markets in the US and EU Atopic Dermatitis A high level of unmet need creates market opportunities Small Cell Lung Cancer and Malignant Mesothelioma Limited R&D activity provides opportunity for early-phase pipeline drugs Esophageal Cancer Treatment paradigms need revolution not evolution The Pharmaceutical Industry Key trends and strategic issues shaping the industry eHealth for the Pharmaceutical Industry What companies need to know about trends in physicians and consumers use of the Internet HIV Change of guard Psoriasis Anti-TNF's lead another indication Osteoarthritis Market sees steady growth Atherosclerosis HDL ApoA-I Carotid MRI and 64-slice CT offer opportunities for future treatment Multiple Sclerosis Disease-modifying efficacy and side effects guide treatment choice Erectile Dysfunction Identifying product differentiation and patient segmentation strategies Melanoma Lucrative commercial opportunities persist Respiratory Syncytial Virus RSV A market yet to reach its full potential Taking CRM to the Next Level Web-assisted relationship and community-building for the pharmaceutical industry The Pharmaceutical Company Outlook to 2011 Financial and Strategic Analysis of the Sales Outlook for Big Pharma Mid Pharma Japan Pharma and Biotech Biosimilars Benchmarking the key players With increasing regulatory clarity and high revenue potential interest in biosimilars increases Obesity Lack of Reimbursement Limits Market Potential Antibacterials Growth in resistance rates drives niche indications Therapeutic Cancer Vaccines A turbulent path from bench to bedside Alzheimer's Disease Prescribing trends indicate that neurologists are not adhering to guidelines Chinese Pharmaceutical Market Overview Regulatory reform and the evolving healthcare market provide opportunities in china Antithrombotics Pipeline products to dampen the impact of patent expiries and cost containment initiatives Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries Pricing and Reimbursement in Oncology Do payers believe oncology drugs offer good value Gynecological Cancers Niche opportunities in advanced disease Biosimilars Regulatory Issues Europe continues to make strides while the US lags behind Drug Delivery Global Industry Guide Biotechnology Global Industry Guide Generics Global Industry Guide Optimizing Sales Force Effectiveness From quantity to quality Inflammatory Bowel Disease Competition Increases for the Biologics Respiratory Tract Infections in the USA The demise of narrow-spectrum antibiotics Emerging eHealth Technologies Key trends impacting the physician-patient relationship Breakthrough Pain Fast-acting players will capture majority market share Osteoarthritis The Wait for a DMOAD Continues Pricing and Reimbursement in Japan Costly healthcare system inefficiencies increase the focus on healthcare cost containment Hormonal Contraceptives New directions in a competitive market Regulator Perceptions in Cancer Evolving opinions about the oncology drug approval process Non-Small Cell Lung Cancer The need to differentiate in an increasingly crowded and fragmented market Innovation in Drug Delivery The future of nanotechnology and non-invasive protein delivery Asthma COPD Targeted therapies on the horizon Epilepsy Pipeline drugs struggle to outshine their marketed predecessors Colorectal Cancer Shaping the future dynamics of colorectal cancer management Molecular Targeted Cancer Therapies More drugs on the market more targets in the pipeline Stakeholder Insight Atrial Fibrillation Limited efficacy and poor safety lead to bleak outlook Stakeholder Insight Supportive Care in Cancer Treatment Some first-generation products proving difficult to dislodge Hip and Knee Replacement Market-Overview of the US and European markets - growth in a mature market Pricing and Reimbursement in Europe-Can the drive for cost effectiveness overcome cost containment? Reformulation Strategies - Comparisons of Past and Future Reformulation Strategies Advanced Life Sciences Cethromycin - Phase III success should allow 'me-too' market entry and above-consensus growth Antihypertensives - New challenges for a maturing market Insulins - Inhalable insulins unlikely to become blockbusters HIV - Extending treatment options Rheumatoid Arthritis - Biologics battle up the treatment algorithm Palatin Technologies Bremelanotide - Competition and regulatory risk cloud potential Sirona Dental Systems - Likely struggle for impressive annual growth despite strong reputation and technology Spectrum Pharmaceuticals Oral Satraplatin - Oral therapy to take share in second-line hormone-refractory prostate cancer market Bipolar Disorder - New treatments for bipolar depression set to drive near-term growth ASCO Review Part I - A summary of highlights presented at the ASCO 2006 Annual Meeting ASCO Review Part II - A summary of highlights presented at the ASCO 2006 Annual Meeting Endo Pharmaceuticals Lidoderm - Physician survey indicates increased use likely to fuel above-consensus sales growth Indevus Pharmaceuticals Sanctura XR - Last-to-market entrant unlikely to make an impact in crowded OAB market Renovis NXY-059 - Safety profile and unmet need could drive approval Santarus Zegerid - Fast-acting formulation gaining momentum in GERD Antidiabetics - Patent expiries and cost containment initiatives balanced by pipeline products Pharmaceutical Outsourcing Part 2 - An Introduction to Drug Discovery Strategies Patients as Consumers - Understanding the Increasing Consumer Level of Influence in Healthcare Orthopedics - Global Industry Guide Asthma - COPD - ICS - LABA combinations continue to dominate Antidyslipidemics - Branded statins beware, generics are amongst you Neuropathic Pain - A Plethora of Patient Segmentation and Product Differentiation Opportunities eCME-Leveraging Online Continuing Medical Education as a Channel of Influence Breast Cancer - A diverse and increasingly crowded pipeline Cancer Overview Emerging Therapeutic and Commercial Opportunities Schizophrenia Parkinson's Disease - Review of Key Commercial Opportunities in the Symptomatic Treatment Market From blockbuster to nichebuster - Niche therapies drive future drugs growth and incentivize R&D investment over sales spending Health Care Equipment & Supplies: Global Industry Guide Ovarian Cancer - Growing importance as secondary indication for targeted therapies Commercial Insight Top 20 Cancer Therapeutics BioPortfolio's BioReports catalogue is one of the most comprehensive sources of specialized life science management reports on the internet. You can search our database by using the links below:
If you represent a publisher who wishes to market via BioPortfolio's BioReports service please contact Peter Barfoot.
Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.
All rights reserved. All other trademarks recognized. Copyright © 1997-2009 - BioPortfolio Limited.
